October 2, 2019 09:23 AM EDT
Deals

As its on­col­o­gy ef­fort gath­ers steam, As­traZeneca sheds an­oth­er lega­cy drug

Natalie Grover

Reporter

On the day As­traZeneca suf­fered a set­back af­ter the US reg­u­la­tor re­ject­ed its triplet for chron­ic ob­struc­tive pul­monary dis­ease — it al­so palmed off …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

Ei­sai ter­mi­nates Phase 3 tri­al of Dravet drug, cit­ing re­cruit­ment chal­lenges

Boston Phar­ma­ceu­ti­cals hits Phase 2 goals as it tries to keep up with MASH com­peti­tors

ALX On­col­o­gy hires Genen­tech, Mi­rati vet as CMO; Af­ter Car­mot, Heather Turn­er has three new roles on tap

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times